<DOC>
	<DOCNO>NCT00880243</DOCNO>
	<brief_summary>The purpose study : 1 . To compare prim Granulocyte-Macrophage Colony-Stimulating Factor ( GM-CSF ) induction consolidation course versus prim . 2 . To compare consolidation time sequential chemotherapy versus four course high dose cytarabine .</brief_summary>
	<brief_title>Effect Priming During Induction Consolidations Younger Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Patients age 15-50 enrol randomly assign receive GM-CSF GM-CSF remission-induction consolidation course chemotherapy . Induction chemotherapy consist timed-sequential chemotherapy include first sequence chemotherapy combine daunorubicin , 80 mg/m2 per day , administer IV short infusion 3 day ( day 1-3 ) , cytarabine , 500 mg/m2 per day IV continuous infusion period . The second sequence , administer 4-day free interval , consist mitoxantrone , 12 mg/m2 per day , administer IV short infusion 2 day ( day 8 9 ) , cytarabine , 500 mg/m2/12h , administer 3-hour infusion 3 day ( day 8-10 ) . Salvage therapy consist cytarabine , 3 g/m2/12h day 1,3,5,7 , combine amsacrine , 100mg/m2 per day day 1 3 . GM-CSF ( Leucomax , recombinant human GM-CSF Escherichia Coli , Schering Plough , Kenilworth , N.J. , USA ) give dose 5Âµg/kg per day , intravenously begin day 1 chemotherapy course continue last day chemotherapy course . Patients achieve CR induction chemotherapy salvage therapy randomly assign consolidation course consist either timed sequential chemotherapy similar ALFA-9000 trial ( P2 arm ) CALGB postremission chemotherapy ( P1 arm ) , include 4 cycle high-dose cytarabine , follow 4 additional maintenance course .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>A morphologically proven diagnosis AML accord WHO classification Serum creatinine &lt; 2N ; AST ALT &lt; 2.5N ; total bilirubin &lt; 2N ( unless relate underlying disease ) . ECOG performance status 0 2 . Women childbearing must use acceptable contraceptive method , must negative serum urine pregnancy test within 2 week prior begin treatment trial . Must able willing give write informed consent Patients M3AML . Patient AML follow diagnosed myeloproliferation patient prior history MDS know 3 month . Patients AML secondary previous treatment cytotoxic chemotherapy radiotherapy ( therapyrelated AML ) . Patient present diagnosis uncontrolled metastatic tumor . Patients uncontrolled severe infection ,</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Priming</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Timed-sequential chemotherapy</keyword>
	<keyword>Prognosis</keyword>
</DOC>